China License Out

Announced Date: 2025-10-17 (October 17, 2025) Licensor (Seller): Hansoh Pharma (China) Licensee (Buyer):  Roche . Asset … [China BD 2025] Hansoh and Roche enters a 1.53 Billion USD License on CDH17 ADC HS-20110Read more

Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Nanjing Leads Biolabs (China) Licensee (Buyer):  Dianthus Therapeutics … [China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF/APRIL inhibitorRead more

Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): HaiHe Biopharma (China) Licensee (Buyer):  Taiho Pharmaceutical  (JP) … [China BD 2025] Haihe Biopharma and Taiho Pharmaceutical enters a License on PI3Kα Inhibitor Risovalisib (CYH33)Read more

Announced Date: 2025-10-08 (October 8, 2025) Asset Name: BTK inhibitor Orelabrutinib; Oral IL-17AA/AF inhibitor; Oral TYK2 … [China BD 2025] InnoCare Pharma and Zenas BioPharma enters 2 Billion USD License on Three Autoimmune Product CandidatesRead more

Asset Name: IBI324 (OLN324) Licensor (Seller): Innovent Biologics (China) Licensee (Buyer):  Ollin Biosciences (US) . Asset … [Unannounced Deal] Innovent and Ollin entered a License for VEGF/Ang2 Bispecific Antibody IBI324 (OLN324)Read more

Announced Date: 2025-09-03 (September 3, 2024) Asset Name: Four siRNA programs  Licensor: Shanghai Argo Biopharmaceutical (China) … [China BD 2025] Argo Biopharma and Novartis enters License and Option on Four siRNA ProgramsRead more

Announced Date: 2025-08-29 (August 29, 2025) Asset Name: KY-0301 Licensor: Novatim (Novatim Immune Therapeutics, China) Licensee … [China BD 2025] Novatim and Radiance enters a 1 billion USD license on MET/EGFR BsADC KY-0301Read more

Announced Date: 2025-08-26 (August 26, 2025) Asset Name: FXS6837 （Other code: XH-S003） Licensor: Fosun Pharma and … [China BD Deal] Fosun and Sitala enters a 670 million license on CFBi FXS6837Read more